Literature DB >> 30295756

Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice.

Desiree Abdurrachim1, Emmy Manders1, Klaas Nicolay1, Eric Mayoux2, Jeanine J Prompers1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30295756     DOI： 10.1093/cvr/cvy246

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  7 in total

1.  Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

Authors:  Mikhail N Kosiborod; Svati H Shah; Senthil Selvaraj; Zhuxuan Fu; Philip Jones; Lydia C Kwee; Sheryl L Windsor; Olga Ilkayeva; Christopher B Newgard; Kenneth B Margulies; Mansoor Husain; Silvio E Inzucchi; Darren K McGuire; Bertram Pitt; Benjamin M Scirica; David E Lanfear; Michael E Nassif; Ali Javaheri; Robert J Mentz
Journal:  Circulation       Date:  2022-05-23       Impact factor: 39.918

2.  Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.

Authors:  Pasquale Paolisso; Luca Bergamaschi; Emanuele Barbato; Carmine Pizzi; Gaetano Santulli; Emanuele Gallinoro; Arturo Cesaro; Felice Gragnano; Celestino Sardu; Niya Mileva; Alberto Foà; Matteo Armillotta; Angelo Sansonetti; Sara Amicone; Andrea Impellizzeri; Gianni Casella; Ciro Mauro; Dobrin Vassilev; Raffaele Marfella; Paolo Calabrò
Journal:  Cardiovasc Diabetol       Date:  2022-05-15       Impact factor: 8.949

Review 3.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.

Authors:  Xiaodan Wang; Jingyu Ni; Rui Guo; Lan Li; Jing Su; Feng He; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2021-03-12       Impact factor: 4.214

4.  Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.

Authors:  B Gaborit; P Ancel; F Kober; A Dutour; A E Abdullah; F Maurice; I Abdesselam; A Calen; A Soghomonian; M Houssays; I Varlet; M Eisinger; A Lasbleiz; F Peiretti; C E Bornet; Y Lefur; L Pini; S Rapacchi; M Bernard; N Resseguier; P Darmon
Journal:  Cardiovasc Diabetol       Date:  2021-03-01       Impact factor: 9.951

5.  Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.

Authors:  Moritz J Hundertmark; Olorunsola F Agbaje; Ruth Coleman; Jyothis T George; Rolf Grempler; Rury R Holman; Hanan Lamlum; Jisoo Lee; Joanne E Milton; Heiko G Niessen; Oliver Rider; Christopher T Rodgers; Ladislav Valkovič; Eleanor Wicks; Masliza Mahmod; Stefan Neubauer
Journal:  ESC Heart Fail       Date:  2021-05-06

Review 6.  Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism.

Authors:  Lingxiang Xie; Yang Xiao; Shi Tai; Huijie Yang; Shenghua Zhou; Zhiguang Zhou
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

Review 7.  Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction.

Authors:  Heidi Budde; Roua Hassoun; Andreas Mügge; Árpád Kovács; Nazha Hamdani
Journal:  Front Physiol       Date:  2022-07-07       Impact factor: 4.755
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.